Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$56.91
-1.9%
$49.90
$1.16
$14.10
$2.47B-0.12189,291 shs275,330 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$14.44
-0.2%
$13.96
$9.12
$72.37
$586.48M1.26869,495 shs351,432 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$5.28
-7.7%
$4.81
$3.79
$12.36
$2.15B0.9116.61 million shs31.50 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$38.03
-1.1%
$33.36
$27.12
$60.90
$2.28B2.41971,088 shs679,091 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-1.88%+3.95%+11.90%+46.94%+21.16%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
0.00%+8.33%+5.87%+18.56%-66.41%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+0.38%+2.13%-8.33%-26.97%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-0.21%+13.08%-2.11%-25.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.1004 of 5 stars
3.31.00.00.02.83.30.0
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
1.995 of 5 stars
3.22.00.00.02.01.70.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.3885 of 5 stars
3.45.00.04.42.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.50
Moderate Buy$30.56111.60% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.33
Hold$7.0032.58% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4032.53% Upside

Current Analyst Ratings Breakdown

Latest KROS, TWST, RXRX, and GMTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
7/3/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$5.00
6/16/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.00
6/10/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$32.00 ➝ $18.00
5/30/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$15.00
5/12/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.00
5/8/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $25.00
5/6/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $8.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$3.55M165.23N/AN/A$14.11 per share1.02
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$58.84M36.48N/AN/A$2.61 per share2.02
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$347.68M6.55N/AN/A$8.07 per share4.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$187.35M-$0.18N/AN/AN/A1.96%0.75%0.69%8/6/2025 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$463.66M-$1.77N/AN/AN/A-961.32%-74.70%-54.02%8/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)

Latest KROS, TWST, RXRX, and GMTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.13N/AN/AN/A$3.83 millionN/A
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/6/2025Q1 2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$0.01$3.62+$3.63$3.62$84.62 million$211.25 million
5/5/2025Q1 2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
19.29
19.29
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.02
4.11
4.11
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
20.60%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
8.43%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
10040.62 million32.25 millionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400406.49 million372.23 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$56.91 -1.09 (-1.88%)
As of 07/11/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Keros Therapeutics stock logo

Keros Therapeutics NASDAQ:KROS

$14.44 -0.03 (-0.21%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$14.20 -0.24 (-1.70%)
As of 07/11/2025 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$5.28 -0.44 (-7.69%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$5.29 +0.01 (+0.17%)
As of 07/11/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$38.03 -0.44 (-1.14%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$37.65 -0.38 (-1.00%)
As of 07/11/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.